The efficacy of ranolazine in improving glycemic parameters in patients with type 2 diabetes mellitus: a meta-analysis

Authors

  • Oliver Allan C. Dampil Department of Medicine, St. Lukes Medical Center Quezon City, Philippines
  • Sybil Claudine R. Luy Department of Medicine, St. Lukes Medical Center Quezon City, Philippines
  • Bayocot Jayson De Lara Department of Medicine, St. Lukes Medical Center Quezon City, Philippines
  • Rojo Rialyn Department of Medicine, St. Lukes Medical Center Quezon City, Philippines
  • Tingchuy Avilyn Raquel Department of Medicine, St. Lukes Medical Center Quezon City, Philippines

DOI:

https://doi.org/10.18203/2349-3259.ijct20232853

Keywords:

Ranolazine, Type 2 diabetes mellitus, Glycemic parameters, Meta-analysis, Diabetes treatment

Abstract

Ranolazine is an anti-anginal drug that mediates its effects by inhibition of cardiac late sodium current. Although it is not indicated for the treatment of type 2 diabetes mellitus (T2DM), several clinical trials have shown that ranolazine was associated with a reduction in HbA1c. The objective of this meta-analysis is to determine the efficacy and safety of ranolazine in improving glycemic control in patients with T2DM. A total of five randomized controlled trials involving 2,680 patients were included in the analysis. The pooled analysis showed that ranolazine may improve glycemic control with a modest decrease in HbA1c and FBS. The difference in HbA1c was -0.38% (95% CI -0.59 to -0.17), favoring ranolazine. Sensitivity analysis showed a difference of HbA1c of -0.49% (CI -0.67, -0.31), still favoring the ranolazine group. There was also a statistically significant difference in fasting glucagon, favoring the ranolazine group (-2.70 pg/ml: 95% CI -5.24 to -0.16). The risk of hypoglycemia with ranolazine was comparable with placebo (RR 1.27 95% CI 0.84 to 1.91). Overall, ranolazine appears to be a safe and effective option for improving glycemic control in patients with T2DM, with a modest decrease in HbA1c and FBS, and a lower risk of hypoglycemia compared to placebo. However, further studies are needed to confirm these findings and to investigate the long-term safety and efficacy of ranolazine in this patient population.

References

NA. Diabetes Mellitus: A Major Risk Factor for Cardiovascular Disease. Circulation. 1999;100(10):1132-3.

Statistics about Diabetes. 2017. Available at: http://www.diabetes.org/diabetesbasics/statistics. Accessed on 25 July 2023.

Adult Treatment Panel III. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation. 2002;106:3143-421.

Herlitz J, Wognsen GB, Karlson BW, Sjöland H, Karlsson T, Caidahl K, et al. Mortality, mode of death and risk indicators for death during 5 years after coronary artery bypass grafting among patients with and without a history of diabetes mellitus. Coron Artery Dis. 2000;11(4):339-46.

Duarte R, Castela S, Reis RP, Correia MJ, Ramos A, Pereira AP, et al. Acute coronary syndrome in a diabetic population-risk factors and clinical and angiographic characteristics. Rev Port Cardiol. 2003;22(9):1077-88.

Chaitman BR, Pepine CJ, Parker JO, Skopal J, Chumakova G, Kuch J, et al. Combination Assessment of Ranolazine in Stable Angina (CARISA) Investigators. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 2004;291(3):309-16.

Belardinelli L, Shryock JC, Fraser H. The mechanism of ranolazine action to reduce ischemia-induced diastolic dysfunction. Eur Heart J. 2006;8:A10-13.

Morrow DA, Scirica BM, Chaitman BR, McGuire DK, Murphy SA, Karwatowska-Prokopczuk E, et al. Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial. Circulation. 2009;119(15):2032-9.

Ning Y, Zhen W, Fu Z, Jiang J, Liu D, Belardinelli L, et al. Ranolazine increases b-cell survival and improves glucose homeostasis in low-dose streptozotocin-induced diabetes in mice. J Pharmacol Exp Ther. 2011;337(1):50-58.

Pettus J, McNabb B, Eckel RH, Skyler JS, Dhalla A, Guan S, et al. Effect of ranolazine on glycaemic control in patients with type 2 diabetes treated with either glimepiride or metformin. Diabetes Obesity Metabol. 2016;18(5):463-74.

Selvarajan S, Dkhar SA, Pillai AA, George M, Jayaraman B, Chandrasekaran A. Comparison of Ranolazine and Trimetazidine on Glycemic Status in Diabetic Patients with Coronary Artery Disease-A Randomized Controlled Trial. J Clin Diagnostic Res. 2015;9(1):OC01-5.

Timmis AD, Chaitman BR, Crager M. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes (subgroup analysis of patients in Combination Assessment of Ranolazine in Stable Angina (CARISA) trial). European Heart J. 2006;27(1):42-8.

Eckel RH, Henry RR, Yue P, Dhalla A, Wong P, Jochelson P, et al. Effect of Ranolazine Monotherapy on Glycemic Control in Subjects with Type 2 Diabetes. Diabetes Care. 2015;38(7):1189-96.

Chaitman BR, Skopal J, Pepine CJ, Parker JO, Chumakova G, Kuch J, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am College Cardiol. 2010;56(14):934-42.

Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Murphy SA, Budaj A, Varshavsky S, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA. 2017;297(16):1775-83.

Kosiborod M, Lam CS, Kohsaka S, Kim DJ, Karasik A, Shaw J, et al. Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study. Journal of the American College of Cardiol. 2018;71(23):2628-39.

Suzuki T, Hirata Y, Yoshida M, Ishii J, Suzuki S, Hinokio Y. Ranolazine suppresses glucagon secretion via inhibition of voltage gated sodium channel Nav1.3 in pancreatic alpha cells. Diabetologia, 2015;58(3):464-72.

Fanaroff A, James SK, Weisz G, Prather K, Anstrom KJ, Mark DB, et al. Ranolazine After Incomplete Percutaneous Coronary Revascularization in Patients with Versus Without Diabetes Mellitus (RIVER-PCI Trial). J Am Coll Cardiol. 2017;69(18):2304-13.

Downloads

Published

2023-09-16